Menarini, Radius Health's Elacestrant Prolongs Progression Free Survival In Breast Cancer

  • The Menarini Group and Radius Health Inc's RDUS data from the phase 3 EMERALD trial evaluating elacestrant for ER+/HER2- advanced or metastatic breast cancer were published in the Journal of Clinical Oncology.
  • The company says that elacestrant is the first oral selective estrogen receptor degrader (SERD) demonstrating a significant improvement in Progression-free survival (PFS) vs. standard of care (SOC) with manageable safety.
  • Elacestrant significantly reduced the risk of disease progression or death by 30% in all patients and 45% in patients with an ESR1 mutation.
  • PFS was prolonged in all patients.
  • PFS rate at 12 months with elacestrant was 22.3% vs. 9.4% with SOC in the overall population and 26.8% vs. 8.2% in the ESR1 mutation population
  • The most common treatment-emergent adverse events (AEs) in patients receiving elacestrant were mild or moderate gastrointestinal events.
  • Price Action: RDUS shares traded higher by 1.71% at $5.94 on the last check Friday.

Posted In: BriefsBiotechNewsHealth CareMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.